Integral Health Asset Management LLC Grows Holdings in DexCom, Inc. (NASDAQ:DXCM)

Integral Health Asset Management LLC increased its stake in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 25.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 150,000 shares of the medical device company's stock after purchasing an additional 30,000 shares during the quarter. Integral Health Asset Management LLC's holdings in DexCom were worth $11,666,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of the stock. Forvis Mazars Wealth Advisors LLC boosted its position in shares of DexCom by 0.7% during the fourth quarter. Forvis Mazars Wealth Advisors LLC now owns 17,481 shares of the medical device company's stock worth $1,359,000 after purchasing an additional 118 shares in the last quarter. Principal Securities Inc. increased its stake in shares of DexCom by 3.4% during the 4th quarter. Principal Securities Inc. now owns 4,069 shares of the medical device company's stock worth $316,000 after purchasing an additional 135 shares during the last quarter. Larson Financial Group LLC boosted its holdings in shares of DexCom by 40.5% during the 4th quarter. Larson Financial Group LLC now owns 475 shares of the medical device company's stock worth $37,000 after buying an additional 137 shares during the period. Level Four Advisory Services LLC boosted its holdings in shares of DexCom by 1.1% during the 4th quarter. Level Four Advisory Services LLC now owns 13,196 shares of the medical device company's stock worth $1,026,000 after buying an additional 150 shares during the period. Finally, Covestor Ltd boosted its holdings in shares of DexCom by 15.6% during the 4th quarter. Covestor Ltd now owns 1,109 shares of the medical device company's stock worth $86,000 after buying an additional 150 shares during the period. 97.75% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the stock. Citigroup upped their price target on shares of DexCom from $101.00 to $104.00 and gave the stock a "buy" rating in a report on Tuesday, March 4th. Cfra Research upgraded shares of DexCom to a "hold" rating in a research report on Friday, March 21st. Barclays upped their price objective on shares of DexCom from $90.00 to $93.00 and gave the stock an "equal weight" rating in a research report on Monday, May 5th. Mizuho assumed coverage on shares of DexCom in a research report on Thursday, April 10th. They set an "outperform" rating and a $85.00 price objective for the company. Finally, Canaccord Genuity Group upped their price target on shares of DexCom from $103.00 to $106.00 and gave the company a "buy" rating in a research report on Friday, May 2nd. Five research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and three have given a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $98.11.

Insider Buying and Selling

In other news, EVP Jereme M. Sylvain sold 7,000 shares of the company's stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $73.83, for a total transaction of $516,810.00. Following the completion of the sale, the executive vice president now owns 135,482 shares of the company's stock, valued at $10,002,636.06. This represents a 4.91% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, COO Jacob Steven Leach sold 14,076 shares of the company's stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total transaction of $990,668.88. Following the sale, the chief operating officer now directly owns 313,497 shares of the company's stock, valued at $22,063,918.86. The trade was a 4.30% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 66,926 shares of company stock valued at $4,734,384 over the last three months. 0.32% of the stock is owned by company insiders.

DexCom Stock Down 0.0%

Shares of DXCM stock traded down $0.03 on Friday, hitting $85.65. The stock had a trading volume of 1,606,510 shares, compared to its average volume of 4,208,037. The business has a 50 day moving average of $71.70 and a 200 day moving average of $77.51. The stock has a market cap of $33.58 billion, a price-to-earnings ratio of 59.89, a price-to-earnings-growth ratio of 2.30 and a beta of 1.43. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.47 and a quick ratio of 1.28. DexCom, Inc. has a 12-month low of $57.52 and a 12-month high of $132.26.

DexCom (NASDAQ:DXCM - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The medical device company reported $0.32 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.33 by ($0.01). The company had revenue of $1.04 billion for the quarter, compared to analysts' expectations of $1.02 billion. DexCom had a return on equity of 30.14% and a net margin of 14.29%. The business's quarterly revenue was up 12.5% on a year-over-year basis. During the same quarter last year, the business posted $0.32 EPS. As a group, analysts expect that DexCom, Inc. will post 2.03 EPS for the current year.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.